MedPath

S100B Protein and Postoperative Cognitive Dysfunction

Completed
Conditions
Postoperative Cognitive Dysfunction
Registration Number
NCT03018522
Lead Sponsor
Antalya Training and Research Hospital
Brief Summary

Primary aim of this study is to evaluate the association between postoperative cognitive dysfunction and increased serum levels of S100B protein after robot-assisted laparoscopic radical prostatectomy.

Detailed Description

The neurocognitive assessment protocol will design to evaluate general cognitive function and identify patients with cognitive dysfunction. Neuropsychological tests of all patients will conduct on the one day prior to surgery, the seventh day after surgery, and the 3rd month after surgery, respectively. According to a consensus statement, cognitive function will assess using a battery of seven neuropsychological tests: Rey Auditory Verbal Learning Test (delayed recall), Trail Making Test (Parts A and B), Digit Span Test (forward and backward), and Grooved Pegboard Test (dominant and non-dominant hands). To determine a normal reference value of cognitive functions, a group of 20 healthy individuals appropriately selected with respect to sex, age and education level without any significant mental or somatic disorders and without operation were recruited as a control group. To determine the cognitive dysfunction, baseline score or time measurement were subtracted from test score and the difference was divided by the standard deviation of the score in the control group. The result was called the Z score. Z score was calculated for each test and, POCD was defined as a Z score greater than 1.96 in at least two of the seven tests, and/or a combined Z score greater than 1.96.

Serum levels of S100B protein will obtain from venous blood samples collected before surgery, after anesthesia induction, at 30 min and 24 h after surgery.

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
89
Inclusion Criteria
  • over 50 years old
  • scheduled for robotic-assisted laparoscopic radical prostatectomy
  • the body mass index ranged from 18 kg/m2 to 25 kg/m2
  • American Society of Anesthesiologists class I, II or III
Exclusion Criteria
  • Patients with previous neurological deficit (symptomatic stroke, hemorrhage, transient ischemic attack)
  • other neurologic disorders (epilepsy, trauma, intra- or extracranial malignancy)
  • psychiatric diseases (schizophrenia, or depressive disorder)
  • alcoholism or any other drug dependence
  • serious hearing or visual impairment

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Score in Neuropsychological TestsChange from neuropsychological test scores at 3 months.

This assessment will be applied before surgery, and 7 days and 3 months after surgery.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Antalya Training and Research Hospital, Department of Anesthesiology and Reanimation

🇹🇷

Antalya, Turkey

Antalya Training and Research Hospital, Department of Anesthesiology and Reanimation
🇹🇷Antalya, Turkey
© Copyright 2025. All Rights Reserved by MedPath